Dyne Therapeutics, Inc. (DYN)
NASDAQ: DYN · IEX Real-Time Price · USD
41.82
+0.43 (1.04%)
Jul 22, 2024, 9:31 AM EDT - Market open
Dyne Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
123
Market Cap
4.06B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 0 | - | - |
Dec 31, 2022 | 0 | - | - |
Dec 31, 2021 | 0 | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Dec 31, 2018 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Perrigo Company | 4.56B |
Alkermes | 1.73B |
Integer Holdings | 1.63B |
Inspire Medical Systems | 660.91M |
Guardant Health | 603.73M |
Ultragenyx Pharmaceutical | 442.59M |
Axsome Therapeutics | 251.02M |
Crinetics Pharmaceuticals | 1.97M |
DYN News
- 4 weeks ago - Dyne Therapeutics Presents New Preclinical Data Demonstrating the Potential of the FORCE™ Platform to Deliver Enzyme Replacement Therapy to Muscle and CNS in Pompe Disease - GlobeNewsWire
- 5 weeks ago - Dyne Therapeutics Presents New Preclinical Data for its Facioscapulohumeral Muscular Dystrophy Program During the FSHD Society International Research Congress - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics to Present at Jefferies Global Healthcare Conference - GlobeNewsWire
- 7 weeks ago - Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares - GlobeNewsWire
- 2 months ago - Up 165% This Year Will Dyne Therapeutics Continue Its Stellar Run? - Forbes
- 2 months ago - Dyne Therapeutics Announces Pricing of $325.5 Million Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces Proposed Public Offering of Common Stock - GlobeNewsWire
- 2 months ago - Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints - GlobeNewsWire